| Aug 6 |
Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update
|
| Aug 5 |
Rhythm Pharmaceuticals Q2 2024 Earnings Preview
|
| Jul 31 |
Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old
|
| Jul 25 |
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts
|
| Jul 23 |
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
|
| Jul 23 |
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
|
| Jul 8 |
Rhythm Pharmaceuticals appoints Garfield as Chief Scientific Officer
|
| Jul 8 |
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
|
| Jun 28 |
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
|
| Jun 12 |
Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
|
